Literature DB >> 35369014

Estimating Kidney Failure Risk Using Electronic Medical Records.

Felipe S Naranjo1,2, Yingying Sang3,4,5, Shoshana H Ballew3,4, Nikita Stempniewicz6, Stephan C Dunning7, Andrew S Levey8, Josef Coresh3,4, Morgan E Grams2,3.   

Abstract

Background: The four-variable kidney failure risk equation (KFRE) is a well-validated tool for patients with GFR <60 ml/min per 1.73 m2 and incorporates age, sex, GFR, and urine albumin-creatinine ratio (ACR) to forecast individual risk of kidney failure. Implementing the KFRE in electronic medical records is challenging, however, due to low ACR testing in clinical practice. The aim of this study was to determine, when ACR is missing, whether to impute ACR from protein-to-creatinine ratio (PCR) or dipstick protein for use in the four-variable KFRE, or to use the three-variable KFRE, which does not require ACR.
Methods: Using electronic health records from OptumLabs Data Warehouse, patients with eGFR <60 ml/min per 1.73 m2 were categorized on the basis of the availability of ACR testing within the previous 3 years. For patients missing ACR, we extracted urine PCR and dipstick protein results, comparing the discrimination of the three-variable KFRE (age, sex, GFR) with the four-variable KFRE estimated using imputed ACR from PCR and dipstick protein levels.
Results: There were 976,299 patients in 39 health care organizations; 59% were women, the mean age was 72 years, and mean eGFR was 47 ml/min per 1.73 m2. The proportion with ACR testing was 19% within the previous 3 years. An additional 2% had an available PCR and 36% had a dipstick protein; the remaining 43% had no form of albuminuria testing. The four-variable KFRE had significantly better discrimination than the three-variable KFRE among patients with ACR testing, PCR testing, and urine dipstick protein levels, even with imputed ACR for the latter two groups. Calibration of the four-variable KFRE was acceptable in each group, but the three-variable equation showed systematic bias in the groups that lacked ACR or PCR testing. Conclusions: Implementation of the KFRE in electronic medical records should incorporate ACR, even if only imputed from PCR or urine dipstick protein levels.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  albuminuria; chronic kidney disease; electronic health records; kidney failure

Mesh:

Substances:

Year:  2021        PMID: 35369014      PMCID: PMC8786004          DOI: 10.34067/KID.0005592020

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  31 in total

1.  Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group.

Authors:  I Giatras; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  1997-09-01       Impact factor: 25.391

Review 2.  Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward.

Authors:  Adeera Levin; Paul E Stevens
Journal:  Kidney Int       Date:  2013-11-27       Impact factor: 10.612

3.  Renal Association Clinical Practice Guideline on vascular access for haemodialysis.

Authors:  Richard Fluck; Mick Kumwenda
Journal:  Nephron Clin Pract       Date:  2011-05-06

4.  Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis.

Authors:  Navdeep Tangri; Morgan E Grams; Andrew S Levey; Josef Coresh; Lawrence J Appel; Brad C Astor; Gabriel Chodick; Allan J Collins; Ognjenka Djurdjev; C Raina Elley; Marie Evans; Amit X Garg; Stein I Hallan; Lesley A Inker; Sadayoshi Ito; Sun Ha Jee; Csaba P Kovesdy; Florian Kronenberg; Hiddo J Lambers Heerspink; Angharad Marks; Girish N Nadkarni; Sankar D Navaneethan; Robert G Nelson; Stephanie Titze; Mark J Sarnak; Benedicte Stengel; Mark Woodward; Kunitoshi Iseki
Journal:  JAMA       Date:  2016-01-12       Impact factor: 56.272

5.  Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality.

Authors:  Juan Jesús Carrero; Morgan E Grams; Yingying Sang; Johan Ärnlöv; Alessandro Gasparini; Kunihiro Matsushita; Abdul R Qureshi; Marie Evans; Peter Barany; Bengt Lindholm; Shoshana H Ballew; Andrew S Levey; Ron T Gansevoort; Carl G Elinder; Josef Coresh
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

Review 6.  Assessing risk in chronic kidney disease: a methodological review.

Authors:  Morgan E Grams; Josef Coresh
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

Review 7.  Strategies for planning the optimal dialysis access for an individual patient.

Authors:  David A Drew; Charmaine E Lok
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-05       Impact factor: 2.894

8.  Kidney Failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) Study: Comparing Ascertainment of Treated and Untreated Kidney Failure in a Cohort Study.

Authors:  Casey M Rebholz; Josef Coresh; Shoshana H Ballew; Blaithin McMahon; Seamus P Whelton; Elizabeth Selvin; Morgan E Grams
Journal:  Am J Kidney Dis       Date:  2015-03-12       Impact factor: 8.860

9.  Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.

Authors:  Kunihiro Matsushita; Josef Coresh; Yingying Sang; John Chalmers; Caroline Fox; Eliseo Guallar; Tazeen Jafar; Simerjot K Jassal; Gijs W D Landman; Paul Muntner; Paul Roderick; Toshimi Sairenchi; Ben Schöttker; Anoop Shankar; Michael Shlipak; Marcello Tonelli; Jonathan Townend; Arjan van Zuilen; Kazumasa Yamagishi; Kentaro Yamashita; Ron Gansevoort; Mark Sarnak; David G Warnock; Mark Woodward; Johan Ärnlöv
Journal:  Lancet Diabetes Endocrinol       Date:  2015-05-28       Impact factor: 32.069

10.  Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression.

Authors:  Tracey Ying; Philip Clayton; Chetana Naresh; Steven Chadban
Journal:  BMC Nephrol       Date:  2018-03-07       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.